SMBC Nikko analyst David Hoang downgraded Gossamer Bio to Neutral from Outperform with a $3 price target.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GOSS:
- Piper says ‘Street overreacted’ to Gossamer data, seralutinib still ‘promising’
- Gossamer Bio Tanks after Phase 2 Study Results in PAH
- Aerovate upgraded to Buy at BTIG after Gossamer study hits endpoint
- Gossamer Bio announces TORREY study meets primary endpoint
- Cantor Fitzgerald biotech analyst hold analyst/industry conference call